Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER COMPRISING EDNRA INHIBITOR AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2023/163497
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating colorectal cancer comprising an EDNRA inhibitor as an active ingredient. Specifically, it was confirmed that the proliferation of colorectal cancer cells decreased and apoptosis increased when EDNRA expression was inhibited, and thus, inhibition of EDNRA can be a treatment mechanism for colorectal cancer, and it was confirmed that APY29 and CGP60474 were screened for EDNRA inhibitor drugs and treating the colorectal cancer cells with APY29 and CGP60474 caused apoptosis. In addition, it was confirmed that when APY29 and CGP60474 compounds selected as EDNRA inhibitors were administered simultaneously with irinotecan, topotecan, or daunorubicin, which are cytotoxic anti-cancer drugs widely used in the treatment of colorectal cancer, the cancer cell apoptosis effect increased, and thus, the cancer treatment effect could be improved via co-administration with anticancer drugs.
Inventors:
KIM JANG SEONG (KR)
JUNG EUNSUN (KR)
BAN HYUN SEUNG (KR)
HAN TAE-SU (KR)
JUNG EUNSUN (KR)
BAN HYUN SEUNG (KR)
HAN TAE-SU (KR)
Application Number:
PCT/KR2023/002511
Publication Date:
August 31, 2023
Filing Date:
February 22, 2023
Export Citation:
Assignee:
KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY (KR)
International Classes:
A61K48/00; A61K31/506; A61K31/7088; A61K31/713; A61P35/00; G01N33/50
Domestic Patent References:
| WO2018029586A1 | 2018-02-15 |
Foreign References:
| US20040009171A1 | 2004-01-15 | |||
| KR20130123522A | 2013-11-13 | |||
| KR102335799B1 | 2021-12-08 | |||
| KR20130073948A | 2013-07-03 |
Other References:
DATABASE Nucleotide 10 June 2020 (2020-06-10), ANONYMOUS : "PREDICTED: Mirounga leonina endothelin receptor type A (EDNRA), mRNA", XP093087231, retrieved from NCBI Database accession no. XM_035022947.1
Attorney, Agent or Firm:
BAE, KIM & LEE IP (KR)
Download PDF: